MX2024009404A - IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASES. - Google Patents
IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASES.Info
- Publication number
- MX2024009404A MX2024009404A MX2024009404A MX2024009404A MX2024009404A MX 2024009404 A MX2024009404 A MX 2024009404A MX 2024009404 A MX2024009404 A MX 2024009404A MX 2024009404 A MX2024009404 A MX 2024009404A MX 2024009404 A MX2024009404 A MX 2024009404A
- Authority
- MX
- Mexico
- Prior art keywords
- macrocycles
- imidazole
- treatment
- autoimmune diseases
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (Ia), (ver Fórmula) (Ia), en donde R2, M1, M2, M3, Q1 y Q2 son como se describen en la presente, y las sales farmacéuticamente aceptables de estos, composiciones que incluyen los compuestos y métodos de uso de los compuestos.The present invention relates to compounds of formula (Ia), (see Formula) (Ia), wherein R2, M1, M2, M3, Q1 and Q2 are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds, and methods of using the compounds.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022075304 | 2022-02-02 | ||
| CN2022137604 | 2022-12-08 | ||
| PCT/EP2023/052218 WO2023148129A1 (en) | 2022-02-02 | 2023-01-31 | Imidazole macrocycles for the treatment of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009404A true MX2024009404A (en) | 2024-08-14 |
Family
ID=85175764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009404A MX2024009404A (en) | 2022-02-02 | 2023-01-31 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASES. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4472739A1 (en) |
| JP (1) | JP2025506393A (en) |
| KR (1) | KR20240145483A (en) |
| CN (1) | CN120641428A (en) |
| AR (1) | AR128413A1 (en) |
| AU (1) | AU2023215702A1 (en) |
| CA (1) | CA3250448A1 (en) |
| CL (1) | CL2024002334A1 (en) |
| CO (1) | CO2024011088A2 (en) |
| CR (1) | CR20240312A (en) |
| IL (1) | IL314136A (en) |
| MX (1) | MX2024009404A (en) |
| PE (1) | PE20241762A1 (en) |
| TW (1) | TW202342483A (en) |
| WO (1) | WO2023148129A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR133199A1 (en) * | 2023-07-10 | 2025-09-03 | Hoffmann La Roche | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| AR133266A1 (en) * | 2023-07-19 | 2025-09-10 | Hoffmann La Roche | Macrocycles for the treatment of autoimmune diseases |
| WO2025021666A1 (en) * | 2023-07-21 | 2025-01-30 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
| WO2025068132A1 (en) | 2023-09-26 | 2025-04-03 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228895A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| US20250333398A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6746712B2 (en) * | 2016-04-07 | 2020-08-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Heterocyclic amides useful as protein regulators |
| WO2019053617A1 (en) * | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
-
2023
- 2023-01-31 JP JP2024545970A patent/JP2025506393A/en active Pending
- 2023-01-31 CN CN202380019951.0A patent/CN120641428A/en active Pending
- 2023-01-31 PE PE2024001698A patent/PE20241762A1/en unknown
- 2023-01-31 WO PCT/EP2023/052218 patent/WO2023148129A1/en not_active Ceased
- 2023-01-31 EP EP23703543.1A patent/EP4472739A1/en active Pending
- 2023-01-31 AU AU2023215702A patent/AU2023215702A1/en active Pending
- 2023-01-31 IL IL314136A patent/IL314136A/en unknown
- 2023-01-31 CA CA3250448A patent/CA3250448A1/en active Pending
- 2023-01-31 CR CR20240312A patent/CR20240312A/en unknown
- 2023-01-31 KR KR1020247028861A patent/KR20240145483A/en active Pending
- 2023-01-31 MX MX2024009404A patent/MX2024009404A/en unknown
- 2023-02-01 AR ARP230100230A patent/AR128413A1/en unknown
- 2023-02-01 TW TW112103466A patent/TW202342483A/en unknown
-
2024
- 2024-08-02 CL CL2024002334A patent/CL2024002334A1/en unknown
- 2024-08-15 CO CONC2024/0011088A patent/CO2024011088A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240312A (en) | 2024-09-04 |
| CL2024002334A1 (en) | 2025-01-17 |
| TW202342483A (en) | 2023-11-01 |
| WO2023148129A1 (en) | 2023-08-10 |
| AR128413A1 (en) | 2024-05-08 |
| PE20241762A1 (en) | 2024-08-28 |
| CN120641428A (en) | 2025-09-12 |
| AU2023215702A1 (en) | 2024-07-25 |
| CO2024011088A2 (en) | 2024-08-30 |
| EP4472739A1 (en) | 2024-12-11 |
| KR20240145483A (en) | 2024-10-07 |
| CA3250448A1 (en) | 2023-08-10 |
| JP2025506393A (en) | 2025-03-11 |
| IL314136A (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009404A (en) | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASES. | |
| CL2019000368A1 (en) | CDK2 / 4/6 inhibitors. | |
| ECSP20060827A (en) | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS INHIBITORS OF A2A / A2B | |
| CO2024017733A2 (en) | Macrocyclic kras inhibitors for cancer treatment | |
| UY38553A (en) | CDK2 INHIBITORS | |
| AR119206A1 (en) | PYRROLO[1,2-c]IMIDAZOLE DERIVATIVES AS EGFR INHIBITORS | |
| CO2025001184A2 (en) | Macrocyclic compounds for cancer treatment | |
| CO2017009891A2 (en) | Inhibitors of transforming growth factor beta inhibitors (tgf-beta) | |
| CL2022002772A1 (en) | Macrocyclic diamines for cancer treatment and combination with adenosine receptor antagonists | |
| CR20220124A (en) | TRIAZOLOPYRIMIDINES AS A2A/A2B INHIBITORS | |
| CO2021013166A2 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of an autoimmune disease | |
| CO2025010435A2 (en) | Tricyclic compounds for cancer treatment | |
| AR133266A1 (en) | Macrocycles for the treatment of autoimmune diseases | |
| UY39303A (en) | HER2 MUTATION INHIBITORS | |
| AR133199A1 (en) | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| UY39625A (en) | TRICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF PARP7 | |
| CR20240533A (en) | Indazole macrocycles and their use | |
| CL2025000161A1 (en) | Cyclic compounds and methods of using same. | |
| CL2025000672A1 (en) | Aminopyrimidine derivatives, CDK2 inhibitors; pharmaceutical composition; use for treating cancer. | |
| ECSP24038829A (en) | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | |
| CO2023017975A2 (en) | Imidazole-containing alk2 kinase inhibitors | |
| AR131717A1 (en) | BICYCLIC IMIDE COMPOUNDS AS TRPA1 INHIBITORS | |
| AR131945A1 (en) | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | |
| CL2025000379A1 (en) | Bicyclic tetrahydrothiazepine derivative compounds, pharmaceutical composition, and use as immunotherapeutic agents. | |
| AR131849A1 (en) | TRICYCLIC COMPOUNDS FOR CANCER TREATMENT |